<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486925</url>
  </required_header>
  <id_info>
    <org_study_id>UESTC-neuSCAN-45</org_study_id>
    <nct_id>NCT03486925</nct_id>
  </id_info>
  <brief_title>Oxytocin Effect on Attention Inhibition</brief_title>
  <official_title>An Eye-tracking Study to Investigate Oxytocin Effect on Attention Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Electronic Science and Technology of China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of intranasal oxytocin (24IU) on cognitive control of attention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The cognitive control of attention towards neutral and emotional stimuli represents a key
      functional domain and disruptions in this domain have been associated with a range of
      psychiatric disorders. Saccadic eye movement tasks have been used to assess individual
      differences in the cognitive control of attention and alterations in psychiatric disorders.
      Recent evidence suggests that the hypothalamic neuropeptide Oxytocin (OXT) may modulate
      attention allocation and regulation. To this end the present randomized between-subject
      placebo-controlled experiment examined whether intranasal OXT modulates behavior in an
      eye-tracking saccade / anti-saccade paradigm in healthy male subjects. The paradigm used
      non-social (neutral shape) as well as social (happy, sad, angry, fear, and neutral faces)
      stimuli to explore emotion-specific effects of OXT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">March 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>emotion-specific saccade latencies</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>comparison between emotion-specific saccade latencies between the treatment groups (in milliseconds)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>emotion-specific error rates</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>comparison between the emotion-specific ratio of unsuccessful anti-saccades between the treatment groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>oxytocin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin treatment</intervention_name>
    <description>intranasal administration of oxytocin (24IU)</description>
    <arm_group_label>oxytocin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo treatment</intervention_name>
    <description>intranasal administration of placebo</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, healthy participants

          -  Non smokers

        Exclusion Criteria:

          -  Previous or current medical, psychiatric, neurological disorder

          -  Regular medication

          -  Use of any psychoactive substances in the 24 hours before experiment

          -  Contra-indications for oxytocin

          -  Contra-indications for eye-tracking data acquisition
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Becker</last_name>
    <phone>18584070309</phone>
    <email>ben_becker@gmx.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>School of Life Science and Technology, University of Electronic Science and Technology of China</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>611731</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Becker, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Electronic Science and Technology of China</investigator_affiliation>
    <investigator_full_name>Benjamin Becker</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>oxytocin, eye-tracking, attention inhibition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

